Plant alkaloid · Fact sheet

Berberine

Berberine has human studies suggesting glucose and lipid effects, but weight-loss evidence is inconsistent. It is not an approved replacement for diabetes or obesity medicines and can cause gastrointestinal symptoms and drug interactions.

Not FDA approvedEarly human evidence

What is Berberine?

Berberine is an alkaloid found in several plants. It is not a peptide or a GLP-1 receptor agonist.

Benefits & claims

Glucose control, weight loss, and lipid changes drive interest. Calling it a natural equivalent of a prescription GLP-1 medicine skips major differences in evidence and mechanism.

What the evidence supports

  • A three-month pilot in adults with type 2 diabetes found improved glucose measures.
  • This does not establish equal long-term benefit or safety to approved medicines, and weight-loss findings remain inconclusive.
Research areas
  • Glucose regulation
  • Lipids
  • Body weight

Dosage & frequency

Human study context

A small diabetes trial supplies a study regimen, but berberine is not an FDA-approved diabetes or weight-loss medicine.

Pilot type 2 diabetes trial

Newly diagnosed adults with type 2 diabetes

Amount
500 mg per dose
Frequency
Three times daily for three months
Route studied or labeled
Oral

Small disease-specific study; not FDA-approved diabetes treatment.

How to read these amounts

An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.

Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences

Formulations, interactions & practical context

Formulation differences

  • Results for berberine hydrochloride are not automatically transferable to dihydroberberine or combination products.

Interactions & precautions

  • NCCIH notes medicine interactions, including cyclosporine; effects on drug exposure need product-specific review.

What is still unresolved

  • A reproducible weight-management regimen and long-term clinical outcomes remain uncertain.

Side effects & risks

  • Nausea, abdominal discomfort, constipation, and diarrhea are reported.
  • Human research shows inhibition of drug-metabolizing enzymes, creating interaction concerns.
  • Pregnancy, breastfeeding, and infant exposure raise specific bilirubin-related safety concerns.

This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.

Clinical research

Early human evidence

A small diabetes pilot and other short studies show metabolic signals. Study quality, formulation differences, and limited long-term outcomes restrict the conclusions.

Studies

Personal experiences

Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.

Explore 3 sourced accounts by reported effect.

Appetite: reported experiences

Mixed account · personal report

Fewer cravings followed by significant illness

A poster described slightly reduced cravings and some weight loss while also dieting, then nausea, diarrhea and later episodes of vomiting, fever, shaking and a racing heart.

Reported use in this account

Product
Berberine pills; formulation not stated
Amount
500 mg initially; later amounts of 1,000 mg and 1,500 mg were reported
Frequency
Daily for the initially stated amount; later frequency not clarified
Route
Not specified clearly
Duration
About four weeks before the first severe episode

Dieting complicates the reported benefit. No diagnosis or product analysis was independently verified; the severe later illness cannot be confidently assigned to berberine.

Read the personal account

Approval status

Berberine has no FDA-approved drug indication for the wellness uses discussed here. Supplement availability is not premarket FDA approval of effectiveness or safety.

Supplement research is not FDA drug approval

Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.

Open questions

  • Reliable long-term weight-loss effects
  • Effects on complications rather than biomarkers alone
  • Which results generalize across formulations

Summary

This does not establish equal long-term benefit or safety to approved medicines, and weight-loss findings remain inconclusive.

Sources

Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.

  1. pubmedBerberine pilot study in type 2 diabetes

    Small three-month study; biomarker outcomes and gastrointestinal adverse effects.

  2. pubmedBerberine and drug-metabolizing enzymes in humans

    Crossover study demonstrating CYP2D6, CYP2C9, and CYP3A4 inhibition.

  3. nihNCCIH: berberine and weight loss

    Evidence limitations, interactions, gastrointestinal symptoms, and infant/pregnancy concerns.

  4. fdaFDA: what approval means for supplements

    Dietary supplements are not approved by FDA for safety and effectiveness before marketing.

How we assess sources · Suggest a correction